The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Propranolol

Criteria

Inclusion Criteria:

• Hemangioma patient ( 0 ~ 9 months old)

• No treatment before

• 10 ~ 20 % volume increase in 2 ~ 4 weeks

• Hemangioma that caused organ function

• Hemangioma that will cause aesthetic problem

Exclusion Criteria:

• Cardiovascular disease (impossible to use propranolol)

• Drug adverse reaction or allergy history (propranolol, steroid)

• Bradycardia, Atrioventricular block, atrial block

• Cardiogenic Shock

• Right heart failure (pulmonary hypertension)

• Congestive heart failure

• Hypotension

• Peripheral nerve disease (moderate)

• Angina

• Hormone deficiency patient

• Pulmonary disease (asthma)

• diabetic ketoacidosis

• laser treatment history